Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

AstraZeneca China President currently under investigation

Our China operations continue under the leadership of the current General Manager of AstraZeneca China

Sumitomo Corporation entered into contract with Revorf

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies

Lupin appoints Claus Jepsen as President, Global Specialty

Mastek partners Innovaccer to transform value-based care and improve patient experience

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC

Enhertu demonstrated clinically meaningful efficacy in previously treated patients

Akums Drugs enters into license and distribution agreement with Triple Hair, Canada

Akums Drugs will undertake this development and commercialization in India

Granules India appoints Ramraj Rangarajulu as President and Head - Formulations Operations

He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024